|POZEN Inc. Elects New Chairman|
CHAPEL HILL, N.C., Jan. 16 /PRNewswire/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that its president and chief executive officer, John R. Plachetka, Pharm. D., has been elected chairman of POZEN Inc. Plachetka, who will continue as president and chief executive officer, succeeds Jacques F. Rejeange who will remain on the board of directors.
"Jacques has provided invaluable guidance over the last year," said Plachetka. "We thank him for leading the company through a period of rapid growth and its initial public offering. We are pleased that he is committed to remain on the board and we intend to draw on his wealth of experience."
Rejeange commented, "It has been a privilege to serve as chairman and contribute to POZEN's successes to date. I look forward to remaining actively involved and contributing to the company's future successes."
The company also announced that Dr. Peter J. Wise, M.D., a co-founder of POZEN and a current member of the board, has been elected to the newly created position of vice chairman. Plachetka said, "We have benefited greatly from Peter's expertise in drug development and he will continue to be instrumental in our future product development activities. His expertise in this area and his leadership abilities will make a significant contribution to our continued growth."
North Carolina-based POZEN Inc. is a pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. The company's initial focus is migraine, where it has built a robust portfolio of four product candidates through a combination of innovation and in-licensing. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN."
POZEN is on the Internet at www.pozen.com